Articles related to MYELOMA
Bispecific Antibody Shows Promise in R/R Multiple Myeloma
Publication: The LancetDesign: Open-label, single-arm study of 157 patients who had undergone a median of six previous lines of therapy and who received at least one dose of teclistamab; 40 patients received the recommended phase II dose of teclistamabResults: Of the 40 receiving the phase II dose, 58% achieved a very good partial response or better; 40% achieved a complete response or better
Hematology September 7th 2021
Clonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates of complete response and cytokine release syndrome severity in the younger than 60 population. However, there was no difference in progression-free or overall survival, regardless of age. Design: Cohort review of 154 patients with NHL or MM receiving CAR T-cells
Hematology August 17th 2021
What “The Princess Bride” Teaches Us About Outcomes in Multiple Myeloma
“It’s inconceivable!” This famous line and exchange from the 1987 classic film The Princess Bride, along with the fates of the characters Vizzini and Inigo Montoya, provide the fulcrum for this Journal of Clinical Oncology (JCO) editorial, which highlights the phase III TOURMALINE-MM1 trial and its seemingly “negative” findings in multiple myeloma (MM). Are we considering the inconceivable? Do we know what the word even means?
Family Medicine/General Practice June 28th 2021
FDA Actions and Updates
From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.
Hematology April 6th 2021
Current Antibody-Based Therapies for the Treatment of Multiple Myeloma
Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.
Hematology November 30th 2020